|
|
|
Info: Your browser does not accept cookies. If you want to put products into your cart and purchase them you need to enable cookies.
Browse
Commercial & Pipeline Insight: Hospital Antibacterials
Detailed forecast (US, JPN, GER, ITA, ESP, UK) for key marketed and pipeline hospital antibiotics. Discussion of key drivers, threats, and strategic analysis of opportunities in a market beset by generic erosion and similarly targeted new entrants.
Commercial and Pipeline Insight: Inflammatory Bowel Disease
Ulcerative colitis and Crohn’s disease are the primary constituents of Inflammatory Bowel Disease, which is estimated to affect approximately 1.8 million people in the seven major markets. Eight years after the launch of Remicade in Crohn’
Commercial and Pipeline Perspectives: Obesity
Datamonitor predicts a somewhat enthusiastic uptake of two agents currently in development by 2015. However, reimbursement is critical to the uptake of new medication, due to the high cost of therapy. If the reimbursable status is not achieved, the ex
Commercial and Pipeline Insight: Psoriasis
There is no cure for psoriasis, which profoundly affects sufferers quality of life, physical and social functioning. There is a particular unmet need for effective long-term therapies for psoriasis. Prevalence is the highest of the autoimmune diseases
Results 1 - 7 of 7
|
|
|
|
